DFTX

Definium Therapeutics, Inc.

Healthcare
Biotechnology
$5.16B market cap

Forecast run · Sep 14, 2026Upside rank 496 of 3,136

Model Signal

ForecastQ Daily Probabilities

55.8%

44.8%

38.7%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$38.89

Price target$64.90

Implied move+66.9%

Analysts12

ForecastQ Portfolios

DFTX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.